glp-1 receptor agonists and cardiovascular outcome trials an update mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia The cardiovascular effects of GLP-1
Description
383,384 Importantly, the activation of AMPK reduces the expression of phosphoglycerate mutase 5 (PGAM5), which plays a promotive role in cell necrosis by contributing to mitochondrial dysfunction and the production of reactive oxygen species (ROS)
17 , 227244 (2021) S
PMID: 16406191
doi: 10.1111/j.1464-5491.2010.03009.x
With an increasing burden of diabetes and obesity, these drugs have the potential to reshape public health policies, redefine preventive care, and alter the economic landscape of the pharmaceutical industry
Acta Pharmacol Sin
